Blindness: The under-rated investment case
By Pooya Hemami, Healthcare Analyst at Edison Group – Blindess is perhaps not the most obvious opportunity for investors to spot. Even in a world where other pharma investments are being rehabilitated by Covid-19, sight loss remains a relatively small and expert-only corner of the market.